Mitochondrial Metal Ion Transport: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Cell Biology
Contributor:
Junjie Luo

The homeostasis of mitochondrial metal ions plays an important role in maintaining mitochondria and cell functions and regulating multiple diseases. In particular, channels and transporters for transporting mitochondrial metal ions are very critical, which can be used as potential targets to treat neurodegeneration, cardiovascular diseases, cancer, diabetes and other metabolic diseases. This review summarizes the current research on several types of mitochondrial metal ion channels/transporters and their functions in cell metabolism and diseases, providing strong evidence and therapeutic strategies for further insights into related diseases.

  • mitochondrial metal ion transport
  • mitochondrial metal ion homeostasis
  • mitochondrial function
  • cell metabolism
  • disease

1. Introduction

Mitochondria are cytoplasmic organelles crucial to life. Since the major function of mitochondria is to produce a large amount of energy ATP, they are called the powerhouse of the cell. However, the functions of mitochondria are multifaceted, far beyond bioenergetics, such as cell metabolism, apoptosis, fatty acid β -oxidation, reactive oxygen species (ROS) signaling, steroid synthesis, and metal ion homeostasis [1][2][3][4][5]. Mitochondria have a double membrane structure, namely mitochondrial inner membrane (MIM) and mitochondrial outer membrane (MOM), both of which contain selective and nonselective ion channels and transporters [6][7]. The MOM with a simple structure is a permeable membrane for small molecules and ions, while the MIM is highly impermeable and its passive transport mode is usually driven by electrochemistry [8][9]. The recently discovered mitochondrial metal ion channels/transporters are mainly located on these mitochondrial membranes, especially the MIM. While some metal ion channels/transporters participate in normal physiological activities, others only play their roles in pathological states, both of which are essential for cell survival and metabolism. Moreover, mitochondrial metal ion channels/transporters are considered to be important communication media between mitochondria and cytoplasm. Unbalanced communication causes disorders of cell metabolism and energy supply, leading to multiple pathologies [10][11].

Impaired metal ion homeostasis at the cellular level is linked to mitochondrial dysfunction [12][13]. The dynamic balance of metal ions inside and outside the mitochondria plays significant roles in numerous cellular physiological processes, including activating ATPase, maintaining ATP production, keeping the homeostasis of mitochondrial volume, regulating the concentration of ROS, controlling signal transduction, and holding the balance of other ion concentrations. Furthermore, it has been reported that the metal ion dyshomeostasis in mitochondria is related to pathological features in neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease [12][14][15]. In addition, diseases related to mitochondrial metal ion dyshomeostasis also include cancer, type 2 diabetes (T2D), heart failure, ischemia and reperfusion injury [16][17][18][19][20]. It is particularly important to note that targeting certain mitochondrial metal ion channels/transporters can treat diseases, such as hypoxic pulmonary artery hypertension, cancer and neurodegenerative disorders [21][22][23].

As far as we know, although the current research on mitochondrial metal ion transport is still limited, it has been found that there are several specific channels/transporters on the inner or outer membrane of mitochondria, which are responsible for transporting different metal cations, such as Ca 2 + , K + , Na + , Mg 2+ , Zn 2+ and Fe 2+ /Fe 3+ ( Table 1 ). Mitochondrial channels/transporters and transports of metal cations are the key to modulating metal ion homeostasis directly or indirectly, which is essential for mitochondrial function, cellular metabolism, health and disease ( Figure 1 ). Herein, our review summarizes the current relevant studies and focuses primarily on several types of mitochondrial metal ion transport and their roles in cell metabolism and diseases. Not only can it provide a reference for in-depth research on the transport of mitochondrial metal ions, but is also expected to develop more disease treatment strategies.

2. Mitochondrial Iron Ion

Mitochondria are the main utilization sites of iron which are transported to the matrix to synthesize iron-sulfur clusters and heme [24]. The precise regulation of iron ions in mitochondria is essential for hemoglobin production, Fe-S cluster protein assembly and heme biosynthesis during red blood cell development [25][26][27]. It is conceivable that mitochondrial iron homeostasis is involved in various hematological diseases. Mitochondrial iron homeostasis and its dysfunctions have been found in sideroblastic anemia and neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, Huntington disease, and Friedreich’s ataxia [25][28][29][30]. Strikingly, iron overload is the primary cause of increased morbidity in thalassemia [31], but the current research on the relationship between mitochondrial iron homeostasis and thalassemia is very rare. In fact, abnormal cellular iron metabolism is largely affected by mitochondrial iron dyshomeostasis, which may lead to iron overload associated side effects. In turn, an iron loss induced by iron chelator triggers mitophagy [32].

MFRN (SLC25A37) belongs to the vertebrate mitochondrial solute carrier protein family, which transports various metabolites and cofactors on the MIM. Some researchers show that the MFRN is a carrier of iron ions into mitochondria, and mitochondria of MFRN mutants disrupt iron ion uptake, leading to severe hypochromic anemia and stagnant red blood cell maturation [33][34][35][36]. In mouse embryonic stem cells, the lack of MFRN causes fibroblasts to stop maturing and inhibits heme synthesis [33]. The disruption of yeast MFRN orthologs MRS3 and MRS4 leads to defects in iron metabolism and mitochondrial Fe-S cluster formation [37][38]. The transferrin/transferrin receptor 2 (Tf/TfR2) transport system has been reported to deliver transferrin-bound iron to mitochondria, which is disrupted in Parkinson’s disease [39]. Another divalent metal transporter called DMT1 on the MOM also transports iron ions [40]. Overexpression of DMT1 is observed to increase the mitochondrial uptake of iron ions driven by proton gradients. Some small solutes and metal ions enter the mitochondrial membrane space through VDAC, which may involve iron uptake. Further research shows that VDAC is one of DMT1 interacting partners, and DMT1–VDAC interactions mediate mitochondrial iron uptake in cells [41]. Interestingly, mitochondrial ferritin (FTMT), as a novel iron-storage protein in mitochondria, participates in regulating iron distribution between cytosol and mitochondrial contents and has a protective effect in pathogenesis of neurodegenerative diseases in cell models [42][43]. It is worth noting that mitochondrial iron ion efflux channels/transporters have not yet been discovered, which requires an in-depth investigation ( Table 1 ).

3. Mitochondrial Manganese Ion

Mitochondria are the main organelles producing ROS, the accumulation of which will cause cell toxicity, accelerated mutagenesis, lipid peroxidation, protein oxidation and cell death. Thus, the primary mechanism to eliminate ROS relies on superoxide dismutase (SOD), including the cytosolic copper/zinc-dependent SOD (Cu/ZnSOD) and the mitochondrial manganese-dependent SOD (MnSOD) [44]. MnSOD is the only SOD isoform present in mitochondria, which requires a manganese ion as a cofactor to execute its antioxidant defense function [45]. At the cellular level, SLC39A8 (ZIP8) and SLC39A14 (ZIP14) have been identified to specifically mediate manganese uptake in mammals [46][47][48], while SLC30A10 (ZnT10) controls manganese efflux from cells [49][50]. However, the manganese ion transport mechanism in mitochondria is still unclear. It has been proposed that manganese ion uptake from cytosol to mitochondria is possibly mediated via MCU or MFRN1 [51]. Cells lacking MCU are more resistant to Mn 2+ toxicity [52]. A potential role of mitochondria-localized SLC39A8 in the regulation of mitochondrial manganese ion transport will be an interesting point in future research. Of note, the potential role for altered Mn homeostasis and toxicity in neurodegenerative disorders has been reported, but whether it is related to mitochondrial manganese ion transport is still unknown [53][54][55].

4. Other Mitochondrial Metal Ions

Actually, there are more types of metal ions in mitochondria, not just those described above. With reference to the method of rapid immunopurification of mitochondria [56][57], we isolated mitochondria from HepG2 cells and measured the content of different mitochondrial metal ions by inductively coupled plasma mass spectrometry (ICP–MS). This ICP–MS method has been reported to provide high accuracy in monitoring various metal ions [58][59]. As shown in Figure 2 , our results demonstrate that the seven most abundant metal elements in mitochondria are K, Ca, Na, Mg, Fe, Mn and Zn, whose mitochondrial transport channels and transporters have attracted great attention from researchers. So, their transport channels and transporters have been discovered more or less. However, Al, Cu, Sn, Ni, Ba and other metal ions whose abundances are closely followed and relatively low should also be considered seriously. On the one hand, what are the functions of these metal ions in mitochondria? Are they related to some mitochondrial diseases? On the other hand, how they are transported into and out of mitochondria? These questions have not yet been fully answered and require further investigation. For instance, aluminum is considered to be an inducer of the mitochondrial permeability transition [60], and aluminum phosphide can induce oxidative stress and mitochondrial damages in cardiomyocytes and isolated mitochondria [61]. Unfortunately, the transport of mitochondrial aluminum ions is still unclear. Another example is about mitochondrial copper ions. The study has found mitochondrial copper homeostasis and its derailment in Wilson disease [62]. Disruption of mitochondrial copper distribution inhibits self-renewal of leukemia stem cells [63]. More interestingly, it has recently been discovered that mitochondrial copper depletion can suppress triple-negative breast cancer [64]. These studies indicate that mitochondrial copper may be a potentially important and non-negligible target in therapy. However, mitochondrial copper ion transport is poorly understood. As for the lower contents of Sn, Ni, Ba and other metal ions, it is not yet clear how they are transported between the cytoplasm and the mitochondrial matrix. In brief, it is necessary to comprehensively investigate the transport of these mitochondrial metal ions in cell metabolism and diseases, which may become a potential target for the treatment of related diseases.

This entry is adapted from the peer-reviewed paper 10.3390/ijms22147525

References

  1. Kauppila, T.E.S.; Kauppila, J.H.K.; Larsson, N.G. Mammalian Mitochondria and Aging: An Update. Cell Metab. 2017, 25, 57–71.
  2. Spinelli, J.B.; Haigis, M.C. The multifaceted contributions of mitochondria to cellular metabolism. Nat. Cell Biol. 2018, 20, 745–754.
  3. Shadel, G.S.; Horvath, T.L. Mitochondrial ROS signaling in organismal homeostasis. Cell 2015, 163, 560–569.
  4. Marchi, S.; Patergnani, S.; Missiroli, S.; Morciano, G.; Rimessi, A.; Wieckowski, M.R.; Giorgi, C.; Pinton, P. Mitochondrial and endoplasmic reticulum calcium homeostasis and cell death. Cell Calcium 2018, 69, 62–72.
  5. Miller, W.L. Steroid hormone synthesis in mitochondria. Mol. Cell. Endocrinol. 2013, 379, 62–73.
  6. O’Rourke, B. Mitochondrial ion channels. Annu. Rev. Physiol. 2007, 69, 19–49.
  7. Passarella, S.; Atlante, A.; Valenti, D.; de Bari, L. The role of mitochondrial transport in energy metabolism. Mitochondrion 2003, 2, 319–343.
  8. Lemeshko, S.V.; Lemeshko, V.V. Metabolically derived potential on the outer membrane of mitochondria: A computational model. Biophys. J. 2000, 79, 2785–2800.
  9. De Marchi, U.; Fernandez-Martinez, S.; de la Fuente, S.; Wiederkehr, A.; Santo-Domingo, J. Mitochondrial ion channels in pancreatic Beta—Cells: Novel pharmacological targets for the treatment of Type 2 diabetes. Br. J. Pharmacol. 2020, 178, 2077–2095.
  10. O’Rourke, B.; Cortassa, S.; Aon, M.A. Mitochondrial ion channels: Gatekeepers of life and death. Physiology 2005, 20, 303–315.
  11. Xia, M.; Zhang, Y.; Jin, K.; Lu, Z.; Zeng, Z.; Xiong, W. Communication between mitochondria and other organelles: A brand-new perspective on mitochondria in cancer. Cell Biosci. 2019, 9, 27.
  12. Nam, E.; Han, J.; Suh, J.M.; Yi, Y.; Lim, M.H. Link of impaired metal ion homeostasis to mitochondrial dysfunction in neurons. Curr. Opin. Chem. Biol. 2018, 43, 8–14.
  13. Pierrel, F.; Cobine, P.A.; Winge, D.R. Metal Ion availability in mitochondria. Biometals Int. J. Role Met. Ions Biol. Biochem. Med. 2007, 20, 675–682.
  14. Matak, P.; Matak, A.; Moustafa, S.; Aryal, D.K.; Benner, E.J.; Wetsel, W.; Andrews, N.C. Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice. Proc. Natl. Acad. Sci. USA 2016, 113, 3428–3435.
  15. Horowitz, M.P.; Greenamyre, J.T. Mitochondrial iron metabolism and its role in neurodegeneration. J. Alzheimer’s Dis. JAD 2010, 20, S551–S568.
  16. Wang, W.; Fan, Y.; Wang, S.; Wang, L.; He, W.; Zhang, Q.; Li, X. Effects of voltage-gated K+ channel on cell proliferation in multiple myeloma. Sci. World J. 2014, 2014, 785140.
  17. Wang, C.H.; Wei, Y.H. Role of mitochondrial dysfunction and dysregulation of Ca(2+) homeostasis in the pathophysiology of insulin resistance and type 2 diabetes. J. Biomed. Sci. 2017, 24, 70.
  18. Ummarino, D. Calcium: Mitochondrial calcium efflux essential for heart function. Nat. Rev. Cardiol. 2017, 14, 317.
  19. Williams, G.S.; Boyman, L.; Lederer, W.J. Mitochondrial calcium and the regulation of metabolism in the heart. J. Mol. Cell. Cardiol. 2015, 78, 35–45.
  20. Wang, W.; Karamanlidis, G.; Tian, R. Novel targets for mitochondrial medicine. Sci. Transl. Med. 2016, 8, 326rv3.
  21. Bachmann, M.; Costa, R.; Peruzzo, R.; Prosdocimi, E.; Checchetto, V.; Leanza, L. Targeting Mitochondrial Ion Channels to Fight Cancer. Int. J. Mol. Sci. 2018, 19, 2060.
  22. Tajti, G.; Wai, D.C.C.; Panyi, G.; Norton, R.S. The Voltage—Gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides. Biochem. Pharmacol. 2020, 181, 114146.
  23. Dong, L.; Li, Y.; Hu, H.; Shi, L.; Chen, J.; Wang, B.; Chen, C.; Zhu, H.; Li, Y.; Li, Q.; et al. Potential therapeutic targets for hypoxia-induced pulmonary artery hypertension. J. Transl. Med. 2014, 12, 39.
  24. Ward, D.M.; Cloonan, S.M. Mitochondrial Iron in Human Health and Disease. Annu. Rev. Physiol. 2019, 81, 453–482.
  25. Gao, J.; Zhou, Q.; Wu, D.; Chen, L. Mitochondrial iron metabolism and its role in diseases. Clin. Chim. Acta Int. J. Clin. Chem. 2021, 513, 6–12.
  26. Lill, R.; Muhlenhoff, U. Iron-sulfur-protein biogenesis in eukaryotes. Trends Biochem. Sci. 2005, 30, 133–141.
  27. Rouault, T.A.; Tong, W.H. Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat. Rev. Mol. Cell Biol. 2005, 6, 345–351.
  28. Mena, N.P.; Urrutia, P.J.; Lourido, F.; Carrasco, C.M.; Nunez, M.T. Mitochondrial iron homeostasis and its dysfunctions in neurodegenerative disorders. Mitochondrion 2015, 21, 92–105.
  29. Urrutia, P.J.; Mena, N.P.; Nunez, M.T. The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders. Front. Pharmacol. 2014, 5, 38.
  30. Isaya, G. Mitochondrial iron-sulfur cluster dysfunction in neurodegenerative disease. Front. Pharmacol. 2014, 5, 29.
  31. Taher, A.T.; Saliba, A.N. Iron overload in thalassemia: Different organs at different rates. Hematol. Am. Soc. Hematology. Educ. Program 2017, 2017, 265–271.
  32. Hara, Y.; Yanatori, I.; Tanaka, A.; Kishi, F.; Lemasters, J.J.; Nishina, S.; Sasaki, K.; Hino, K. Iron loss triggers mitophagy through induction of mitochondrial ferritin. EMBO Rep. 2020, 21, e50202.
  33. Shaw, G.C.; Cope, J.J.; Li, L.; Corson, K.; Hersey, C.; Ackermann, G.E.; Gwynn, B.; Lambert, A.J.; Wingert, R.A.; Traver, D.; et al. Mitoferrin is essential for erythroid iron assimilation. Nature 2006, 440, 96–100.
  34. Zhao, L.; Xia, Z.; Wang, F. Zebrafish in the sea of mineral (iron, zinc, and copper) metabolism. Front. Pharmacol. 2014, 5, 33.
  35. Finoshin, A.D.; Adameyko, K.I.; Mikhailov, K.V.; Kravchuk, O.I.; Georgiev, A.A.; Gornostaev, N.G.; Kosevich, I.A.; Mikhailov, V.S.; Gazizova, G.R.; Shagimardanova, E.I.; et al. Iron metabolic pathways in the processes of sponge plasticity. PLoS ONE 2020, 15, e0228722.
  36. Seguin, A.; Jia, X.; Earl, A.M.; Li, L.; Wallace, J.; Qiu, A.; Bradley, T.; Shrestha, R.; Troadec, M.B.; Hockin, M.; et al. The mitochondrial metal transporters mitoferrin1 and mitoferrin2 are required for liver regeneration and cell proliferation in mice. J. Biol. Chem. 2020, 295, 11002–11020.
  37. Muhlenhoff, U.; Stadler, J.A.; Richhardt, N.; Seubert, A.; Eickhorst, T.; Schweyen, R.J.; Lill, R.; Wiesenberger, G. A specific role of the yeast mitochondrial carriers MRS3/4p in mitochondrial iron acquisition under iron-limiting conditions. J. Biol. Chem. 2003, 278, 40612–40620.
  38. Zhang, Y.; Lyver, E.R.; Knight, S.A.; Lesuisse, E.; Dancis, A. Frataxin and mitochondrial carrier proteins, Mrs3p and Mrs4p, cooperate in providing iron for heme synthesis. J. Biol. Chem. 2005, 280, 19794–19807.
  39. Mastroberardino, P.G.; Hoffman, E.K.; Horowitz, M.P.; Betarbet, R.; Taylor, G.; Cheng, D.; Na, H.M.; Gutekunst, C.A.; Gearing, M.; Trojanowski, J.Q.; et al. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson’s disease. Neurobiol. Dis. 2009, 34, 417–431.
  40. Wolff, N.A.; Garrick, M.D.; Zhao, L.; Garrick, L.M.; Ghio, A.J.; Thevenod, F. A role for divalent metal transporter (DMT1) in mitochondrial uptake of iron and manganese. Sci. Rep. 2018, 8, 211.
  41. Hamdi, A.; Roshan, T.; Sheftel, A.; Ponka, P. Interaction of Transferrin-Endosomes with Mitochondria: Implications for Iron Transport to Ferrochelatase in Erythroid Cells. Blood 2015, 126, 407.
  42. Gao, G.; Chang, Y.Z. Mitochondrial ferritin in the regulation of brain iron homeostasis and neurodegenerative diseases. Front. Pharmacol. 2014, 5, 19.
  43. Yang, H.; Yang, M.; Guan, H.; Liu, Z.; Zhao, S.; Takeuchi, S.; Yanagisawa, D.; Tooyama, I. Mitochondrial ferritin in neurodegenerative diseases. Neurosci. Res. 2013, 77, 1–7.
  44. Ito, H.; Kurokawa, H.; Matsui, H. Mitochondrial reactive oxygen species and heme, non-heme iron metabolism. Arch. Biochem. Biophys. 2021, 700, 108695.
  45. Karnati, S.; Luers, G.; Pfreimer, S.; Baumgart-Vogt, E. Mammalian SOD2 is exclusively located in mitochondria and not present in peroxisomes. Histochem. Cell Biol. 2013, 140, 105–117.
  46. Boycott, K.M.; Beaulieu, C.L.; Kernohan, K.D.; Gebril, O.H.; Mhanni, A.; Chudley, A.E.; Redl, D.; Qin, W.; Hampson, S.; Kury, S.; et al. Autosomal—Recessive Intellectual Disability with Cerebellar Atrophy Syndrome Caused by Mutation of the Manganese and Zinc Transporter Gene SLC39A8. Am. J. Hum. Genet. 2015, 97, 886–893.
  47. Park, J.H.; Hogrebe, M.; Gruneberg, M.; DuChesne, I.; von der Heiden, A.L.; Reunert, J.; Schlingmann, K.P.; Boycott, K.M.; Beaulieu, C.L.; Mhanni, A.A.; et al. SLC39A8 Deficiency: A Disorder of Manganese Transport and Glycosylation. Am. J. Hum. Genet. 2015, 97, 894–903.
  48. Tuschl, K.; Meyer, E.; Valdivia, L.E.; Zhao, N.; Dadswell, C.; Abdul-Sada, A.; Hung, C.Y.; Simpson, M.A.; Chong, W.K.; Jacques, T.S.; et al. Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism-dystonia. Nat. Commun. 2016, 7, 11601.
  49. Hutchens, S.; Liu, C.; Jursa, T.; Shawlot, W.; Chaffee, B.K.; Yin, W.; Gore, A.C.; Aschner, M.; Smith, D.R.; Mukhopadhyay, S. Deficiency in the manganese efflux transporter SLC30A10 induces severe hypothyroidism in mice. J. Biol. Chem. 2017, 292, 9760–9773.
  50. Mercadante, C.J.; Prajapati, M.; Conboy, H.L.; Dash, M.E.; Herrera, C.; Pettiglio, M.A.; Cintron-Rivera, L.; Salesky, M.A.; Rao, D.B.; Bartnikas, T.B. Manganese transporter Slc30a10 controls physiological manganese excretion and toxicity. J. Clin. Investig. 2019, 129, 5442–5461.
  51. Liu, Q.; Barker, S.; Knutson, M.D. Iron and manganese transport in mammalian systems. Biochim. Biophys. Acta. Mol. Cell Res. 2021, 1868, 118890.
  52. Kamer, K.J.; Sancak, Y.; Fomina, Y.; Meisel, J.D.; Chaudhuri, D.; Grabarek, Z.; Mootha, V.K. MICU1 imparts the mitochondrial uniporter with the ability to discriminate between Ca(2+) and Mn(2+). Proc. Natl. Acad. Sci. USA 2018, 115, E7960–E7969.
  53. Bowman, A.B.; Kwakye, G.F.; Herrero Hernandez, E.; Aschner, M. Role of manganese in neurodegenerative diseases. J. Trace Elem. Med. Biol. Organ Soc. Miner. Trace Elem. 2011, 25, 191–203.
  54. Mezzaroba, L.; Alfieri, D.F.; Colado Simao, A.N.; Vissoci Reiche, E.M. The role of zinc, copper, manganese and iron in neurodegenerative diseases. Neurotoxicology 2019, 74, 230–241.
  55. Liu, Z.Q.; Liu, K.; Liu, Z.F.; Cong, L.; Lei, M.Y.; Ma, Z.; Li, J.; Deng, Y.; Liu, W.; Xu, B. Manganese-induced alpha-synuclein overexpression aggravates mitochondrial damage by repressing PINK1/Parkin-mediated mitophagy. Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2021, 152, 112213.
  56. Chen, W.W.; Freinkman, E.; Sabatini, D.M. Rapid immunopurification of mitochondria for metabolite profiling and absolute quantification of matrix metabolites. Nat. Protoc. 2017, 12, 2215–2231.
  57. Chen, W.W.; Freinkman, E.; Wang, T.; Birsoy, K.; Sabatini, D.M. Absolute Quantification of Matrix Metabolites Reveals the Dynamics of Mitochondrial Metabolism. Cell 2016, 166, 1324–1337.
  58. Figueroa, J.A.; Stiner, C.A.; Radzyukevich, T.L.; Heiny, J.A. Metal ion transport quantified by ICP-MS in intact cells. Sci. Rep. 2016, 6, 20551.
  59. Nicolli, A.; Trevisan, A.; Bortoletti, I.; Pozzuoli, A.; Ruggieri, P.; Martinelli, A.; Gambalunga, A.; Carrieri, M. Biological Monitoring of Metal Ions Released from Hip Prostheses. Int. J. Environ. Res. Public Health 2020, 17, 3223.
  60. Toninello, A.; Clari, G.; Mancon, M.; Tognon, G.; Zatta, P. Aluminum as an inducer of the mitochondrial permeability transition. J. Biol. Inorg. Chem. JBIC A Publ. Soc. Biol. Inorg. Chem. 2000, 5, 612–623.
  61. Khezri, S.; Sabzalipour, T.; Jahedsani, A.; Azizian, S.; Atashbar, S.; Salimi, A. Chrysin ameliorates aluminum phosphide-induced oxidative stress and mitochondrial damages in rat cardiomyocytes and isolated mitochondria. Environ. Toxicol. 2020, 35, 1114–1124.
  62. Zischka, H.; Einer, C. Mitochondrial copper homeostasis and its derailment in Wilson disease. Int. J. Biochem. Cell Biol. 2018, 102, 71–75.
  63. Singh, R.P.; Jeyaraju, D.V.; Voisin, V.; Hurren, R.; Xu, C.; Hawley, J.R.; Barghout, S.H.; Khan, D.H.; Gronda, M.; Wang, X.; et al. Disrupting Mitochondrial Copper Distribution Inhibits Leukemic Stem Cell Self-Renewal. Cell Stem Cell 2020, 26, 926–937.
  64. Cui, L.; Gouw, A.M.; LaGory, E.L.; Guo, S.; Attarwala, N.; Tang, Y.; Qi, J.; Chen, Y.S.; Gao, Z.; Casey, K.M.; et al. Mitochondrial copper depletion suppresses Triple—Negative breast cancer in mice. Nat. Biotechnol. 2021, 39, 357–367.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Feedback